The Dynamic Biosensors GmbH Martinsried-based company has completed a Series B financing round totaling five million euros. The patented analysis system of the protein analytics company, founded in 2012, enables its customers, pharmaceutical manufacturers, to produce active medical pharmaceutical ingredients quickly, precisely, and efficiently.
As a new investor, the BayBG Bavarian Investment Company while the existing investors, including UnternehmerTUM Venture Capital Partners or Bavaria Capital, increased their commitment.
“This creates the conditions for an expansion of the product range and an expansion of sales and marketing activities,”
so Dr. Ulrich Rant, Managing Director of Dynamic Biosensors.
Check medications easily and reliably
The patented biochip technology (switchSENSE) developed by Dynamic Biosensors is used to test the effectiveness of medications:
"Pharmaceutical researchers can (...) quickly determine whether a new drug will reach its target in the body and effectively combat disease. Biosensor technology provides a very high level of information and insight,"
justified BayBG-Investment manager Otto Hopfner the commitment of the Bavarian Investment Company.
